ENROLLED
2019 Regular Session
HOUSE RESOLUTION NO. 257
BY REPRESENTATIVE HOFFMANN
A RESOLUTION
To urge and request the Louisiana Department of Health to make changes necessary to
eliminate prior authorization requirements while controlling costs in the Medicaid
program for buprenorphine/naloxone and naltrexone for opioid use disorder
treatment.
WHEREAS, medication treatments for opioid use disorder are effective and are the
current standard of care; and
WHEREAS, unnecessary prior authorizations create a barrier for patient access to
medication treatments and increase administrative complexity for providers; and
WHEREAS, the amount that the state pays for medication treatments should reflect
the value that medication treatments bring through improved clinical outcomes among
Medicaid members.
THEREFORE, BE IT RESOLVED that the House of Representatives of the
Legislature of Louisiana does hereby urge and request the Louisiana Department of Health
to make changes necessary to eliminate prior authorization requirements in the Medicaid
program for all formulations of buprenorphine/naloxone and naltrexone.
BE IT FURTHER RESOLVED that the department should pursue value-based
payment arrangements, as have been successful in other state Medicaid programs, to increase
access to buprenorphine/naloxone and naltrexone products in a cost-effective manner that
ensures that Medicaid members benefit from state expenditures for these drugs.
BE IT FURTHER RESOLVED that the department should ensure that quantity limits
placed on medications to treat opioid use disorder are aligned with the American Society of
Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the
Treatment of Addiction Involving Opioid Use.
Page 1 of 2 HR NO. 257 ENROLLED
BE IT FURTHER RESOLVED that a copy of this Resolution be transmitted to the
secretary of the Louisiana Department of Health.
SPEAKER OF THE HOUSE OF REPRESENTATIVES
Page 2 of 2